Graphite Bio Enrolls First Patient in Phase I/II Clinical Trial of GPH101 for Sickle Cell Disease

Graphite Bio, Inc. announced that the first patient has been enrolled in the company’s Phase I/II clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease.